 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc., NASDAQ: TSHA, a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced a multi-year collaboration with AllStripes formerly RDMD, a healthcare technology company dedicated to accelerating research for patients with rare diseases, during which Taysha will leverage 